In Vitro Lung Model Market Size To Hit 1,549.94 Mn By 2032

The global in vitro lung model market size was estimated at around USD 310.83 million in 2022 and it is projected to hit around USD 1,549.94 million by 2032, growing at a CAGR of 17.43% from 2023 to 2032.

Key Pointers

• North America led the market with largest market share of 45% in 2022.
• By Type, the 2D model types segment held the largest revenue share of 62% in 2022.
• By Type, the 3D model segment is anticipated to grow at the fastest CAGR from 2023 to 2032
• By Application, the drug discovery and toxicology studies segment dominated the global market in 2022.
• By Application, the 3D model development segment is predicted to grow at the fastest during forecast period.
• By End-use, the pharmaceutical & biotechnology companies end-use segment led the market in 2022

The in vitro lung model market presents a dynamic landscape within the biomedical research, pharmaceutical development, and respiratory health studies. This market is characterized by the emergence of innovative technologies and methodologies aimed at replicating the intricate complexities of the human lung in an in vitro setting. As a pivotal component of modern research, the in vitro lung model market plays a crucial role in advancing our understanding of respiratory diseases and fostering efficient drug development processes.

Get a Sample: https://www.visionresearchreports.com/report/sample/40996

Market Growth

The growth of the in vitro lung model market is propelled by several key factors that collectively contribute to its expanding influence in biomedical research and pharmaceutical development. One significant driver is the escalating incidence of respiratory diseases globally, prompting an increased demand for advanced in vitro models. These models, leveraging technologies like cell culture systems, microfluidic devices, and biomimetic scaffolds, allow for the meticulous simulation of the complex physiological conditions of the human lung. Moreover, the market benefits from a surge in collaborations and partnerships among research institutions, pharmaceutical companies, and technology providers, fostering innovation and accelerating advancements in the field. Regulatory emphasis on alternatives to traditional testing methods, coupled with continuous technological advancements, further enhances the market’s prospects. As the industry addresses challenges related to standardization and reproducibility, the in vitro lung model market is poised for sustained growth, offering a promising avenue for ethical and compliant research practices in the exploration of respiratory health and drug development.

Report Scope of the In Vitro Lung Model Market

Market Dynamics

Drivers

• Rise of Microfluidic Devices: Microfluidic devices play a pivotal role in the in vitro lung model market, providing precise control over fluid dynamics and cellular microenvironments. These devices enable the creation of realistic lung models, allowing researchers to study airflow patterns, drug diffusion, and cell-to-cell interactions with greater accuracy.
• Utilization of Biomimetic Scaffolds: Biomimetic scaffolds are instrumental in recreating the structural complexity of the lung tissue. The adoption of these scaffolds in in vitro models provides a three-dimensional framework that closely mimics native tissue architecture, enhancing the physiological relevance of the models.

Restraints

• Complexity in Mimicking In Vivo Conditions: The intricate nature of the human lung and its microenvironment presents a significant challenge in accurately mimicking in vivo conditions in in vitro models. Achieving a faithful representation of the physiological complexity of the lung remains a hurdle, limiting the translatability of research findings to clinical applications.
• Ethical Considerations and Validation: While in vitro lung models offer an ethical alternative to traditional animal testing, ethical considerations persist. Ensuring the ethical use and validation of these models, along with addressing concerns about their predictive value, represents a restraint in the market’s widespread acceptance.

Opportunities

• Expansion into Drug Repurposing: In vitro lung models offer an opportunity to explore drug repurposing strategies. By simulating the complex lung microenvironment, researchers can efficiently assess existing drugs for their efficacy against respiratory diseases, potentially identifying novel therapeutic applications and accelerating the drug development process.
• Focus on Environmental Toxin Studies: In vitro lung models offer unique opportunities for studying the impact of environmental toxins on respiratory health. The ability to simulate exposure scenarios and assess the toxicological effects on lung cells provides valuable insights, contributing to our understanding of environmental factors contributing to respiratory diseases.

Type Insights

2D model types segment dominated the market with a revenue share of 62% in 2022 due to their convenience, efficiency, and comprehensive nature. 2D models have been relatively simple to set up and maintain, making them accessible to a wide range of researchers, which helps in understanding tissue engineering or complex culture systems. Furthermore, 2D cultures are well-suited for high throughput screening, allowing researchers to test a large number of compounds or conditions in a relatively short time. Thus, high throughput screening plays a pivotal role in the dominance of this segment.

The 3D model segment is anticipated to grow at the fastest CAGR from 2023 to 2032 owing to its ability to mimic the 3D structure of lungs, including complex interactions between different cell types, the extracellular matrix, and the spatial distribution of cells. Moreover, 3D models allow researchers to recreate the in vitro microenvironment of the lung to a greater extent than 2D models, thus with such advantages over 2D models, the 3D model is expected to witness a lucrative growth in the coming years.

Application Insights

Drug discovery and toxicology studies segment dominated the global market in 2022. In vitro lung models provide a highly controlled and efficient platform for drug screening, which helps pharmaceutical companies and researchers to develop potential drugs to tackle the rising prevalence of respiratory diseases. Moreover, the growing ethical and regulatory push to reduce and replace animal testing further drives the importance of in vitro models in drug development and toxicology studies.

The 3D model development segment is anticipated to grow at the fastest CAGR from 2023 to 2032. 3D model provides a more accurate representation of the three-dimensional architecture and complexity of the human lung compared to 2D models. This increased physiological relevance, which is crucial for understanding lung biology and disease mechanisms, makes them a reliable model to study complex lung structures. Thus, with such parameters the demand for 3D models has increased, contributing to segment growth.

End-use Insights

The pharmaceutical & biotechnology companies end-use segment led the market in 2022 due to their critical role in drug development and research. The pharmaceutical and biotechnology companies rely on in vitro lung models to evaluate the safety and efficacy of new drugs, since they are crucial tools for screening potential drug candidates. Moreover, the high throughput screening capability of in vitro lung models assists pharmaceutical and biotechnology companies in efficiently evaluating numerous potential drugs within a short timeframe further driving the segment dominance.

On the other hand, the academic and research institutes segment is projected to exhibit the fastest growth from 2023 to 2032 due to its pivotal role in advancing scientific understanding and developing novel therapies for respiratory diseases. Moreover, academic institutions use in vitro lung models for teaching and training purposes, to educate the next generation of scientists, researchers, and healthcare professionals. Thus, teaching and training further drive the adoption of in vitro lung models in academic settings.

Regional Insights

North America dominated the market with largest market share of 45% in 2022. Increasing research onlung disorders is likely to create growth opportunities for the market within the region. For instance, according to the International Agency for Research on Cancer’s (IARC) GLOBOCAN, the region reported 254,000 cases of lung cancer in 2020 and is estimated to increase the number by 352,000 till 2040. Thus, such a high number of lung cancers in the region boosts the overall market growth.

Moreover, the presence of a significant number of pharmaceutical and biotechnology companies, as well as academic research institutions further drives the regional market growth. Asia Pacific is expected to register lucrative growth from 2023 to 2032 due to the development of healthcare as well as R&D infrastructure, increased investment in R&D in the region, and improvement in the regulatory framework in developing economies, such as Australia and India among others.

Key Companies

• Epithelix
• MATTEK
• Lonza
• Emulate
• AlveoliX AG
• Nortis
• CN Bio Innovations Ltd.
• MIMETAS
• InSphero
• ATTC Global

Recent Developments

ImmuONE raised USD 2.48 million in November 2023 to create a lung model as a substitute for using animals in drug testing. This is anticipated to grow the clientele for the business.

BICO subsidiaries CELLINK, MatTek, and Visikol announced a joint venture in September 2021 that sought to create a contract research organization (CRO) that provided comprehensive bioprinting services. Through their combined efforts, the three organizations are able to give their consumers comprehensive services because of their combined knowledge. Through this partnership, CELLINK, MatTek, and Visikol give their customers access to a variety of services provided by all three companies.

In Vitro Lung Model Market Report Segmentations:

By Type

• 2D Model
• 3D Model

By Application

• Drug Discovery & Toxicology Studies
• Physiological Research
• 3D Model Development
• Others

By End-use

• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)